Patent US5116840A successfully refreshed from Google Patents.
US5116840A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Polycyclic quinoline, naphthyridine and pyrazinopyridine derivatives
Assignee: Merck Sharp & Dohme LLC
•
Filing: 1990-08-31
•
Granted: 1992-05-26
•
Expires: 2010-08-31
Abstract
Abstract Novel polycyclic quinoline, naphthyridine and pyrazinopyridine derivatives are disclosed which are useful for treating allergic reactions, inflammation, peptic ulcers, hypertension, and hyperproliferative skin diseases and for suppressing the immune response in mammals. Methods for preparing said compounds are also disclosed.
Inventors
- 👤 Ashit K. Ganguly
- 👤 Richard J. Friary
- 👤 John H. Schwerdt
- 👤 Marvin I. Siegel
- 👤 Sidney R. Smith
- 👤 Vera A. Seidl
- 👤 Edmund J. Sybertz
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 09:44
CPC Classifications
C; C07; C07D; C07D471/00; C07D471/02; C07D471/04; C07D221/00; C07D221/02; C07D221/04; C07D221/06; C07D221/16; C07D471/12; C07D471/14; C07D491/00; C07D491/12; C07D491/14; C07D495/00; C07D495/12; C07D495/14
Claims Analysis
Total Claims: 9
Claim 1
Independent Claim
10 words
A compound having the name: 5-(3-chlorophenyl)-5,6,7,8-tetrahydro-9H-cyclopenta-[5,6]pyrido[2,3-b]pyrazin-9-one; 5-(3,4-dichlorophenyl)-5,6,7,8,-tetrahydro-9H-cyclopenta[5,6]pyrido[2,3-b]pyrazin-9-one; 5,6,7,8-tetrahydro-5-(3-nitrophenyl)-9H-cyclopenta[5,6]pyrido[2,3-b]pyrazine-9-one; or 5,6,7,8-tetrahydro-5-phenyl-9H-cyclopenta[5,6]pyrido[2,3]pyrazin-9-one.
Claim 2
Dependent Claim
10 words
A compound having the name: 5-(3-chlorophenyl)-5,6,7,8-tetrahydro-9H-cyclopenta-[5,6]pyrido[2,3-b]pyrazin-9-one; 5-(3,4-dichlorophenyl)-5,6,7,8,-tetrahydro-9H-cyclopenta[5,6]pyrido[2,3-b]pyrazin-9-one; 5,6,7,8-tetrahydro-5-(3-nitrophenyl)-9H-cyclopenta[5,6]pyrido[2,3-b]pyrazine-9-one; or 5,6,7,8-tetrahydro-5-phenyl-9H-cyclopenta[5,6]pyrido[2,3]pyrazin-9-one.
Claim 3
Dependent Claim
19 words
A pharmaceutical composition which comprises a compound as defined in claim 1 in combination with a pharamaceutically acceptable carrier.
Claim 4
Dependent Claim
30 words
A method for treating allergic reactions in a mammel in need of such treatment which comprises administering to said mammal an effective amount of a compound defined in claim 1.
Claim 5
Dependent Claim
29 words
A method for treating inflammation in a mammal in need of such treatment which comprises administering to said mammal an effective amount of a compound defined in claim 1.
Claim 6
Dependent Claim
30 words
A method for treating peptic ulcers in a mammal in need of such treatment which comprises administering to said mammal an effective amount of a compound defined in claim 1.
Claim 7
Dependent Claim
29 words
A method for treating hypertension in a mammal in need of such treatment which comprises administering to said mammal an effective amount of a compound defined in claim 1.
Claim 8
Dependent Claim
26 words
A method for treating hyperproliferative skin disease in a mammal which comprises administering to said mammal an effective amount of a compound defined in claim 1.
Claim 9
Dependent Claim
32 words
A method for suppressing the immune response in a mammal in need of such treatment which comprises administering to said mammal an effective immunosuppressive amount of a compound defined in claim 1.
References Cited (Backward Citations)
FR1585099A
Cited
US3931205A
Cited
US3931199A
Cited
US3947449A
Cited
EP0127135A2
Cited
US4680298A
Cited
US4680297A
Cited
US4596809A
Cited
US4687774A
Cited
US4760073A
Cited
US4801589A
Cited
US4882332A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-05-26 | 1995-11-25 | 1996-05-26 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-05-26 | 1999-11-25 | 2000-05-26 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-05-26 | 2003-11-25 | 2004-05-26 | $7700.00 | Window Closed / Lapsed |